PUBLICATION

Blockage of Lysophosphatidic Acid Signaling Improves Spinal Cord Injury Outcomes

Authors
Goldshmit, Y., Matteo, R., Sztal, T., Ellett, F., Frisca, F., Moreno, K., Crombie, D., Lieschke, G.J., Currie, P.D., Sabbadini, R.A., and Pebay, A.
ID
ZDB-PUB-120724-25
Date
2012
Source
The American journal of pathology   181(3): 978-992 (Journal)
Registered Authors
Currie, Peter D., Ellett, Felix, Goldshmit, Yona, Lieschke, Graham J., Sztal, Tamar Esther
Keywords
none
MeSH Terms
  • Animals
  • Antibodies, Monoclonal/pharmacology
  • Apoptosis/drug effects
  • CHO Cells
  • Cell Death/drug effects
  • Cell Proliferation/drug effects
  • Cell Survival/drug effects
  • Cricetinae
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Inflammation/complications
  • Inflammation/pathology
  • Lysophospholipids/antagonists & inhibitors*
  • Lysophospholipids/metabolism
  • Lysophospholipids/pharmacology
  • Mice
  • Microglia/drug effects
  • Microglia/pathology
  • Motor Activity/drug effects
  • Neurites/drug effects
  • Neurites/metabolism
  • Neuroprotective Agents/pharmacology
  • Receptors, Lysophosphatidic Acid/metabolism
  • Recovery of Function*/drug effects
  • Signal Transduction*/drug effects
  • Spinal Cord Injuries/complications
  • Spinal Cord Injuries/pathology*
  • Spinal Cord Injuries/physiopathology
  • Zebrafish
PubMed
22819724 Full text @ Am. J. Pathol.
Abstract

Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA's effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA's effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI.

Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutation and Transgenics
Human Disease / Model Data
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Errata and Notes